Search stocks

Find any stock by ticker or company name

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz haqimizda

Biz bilan bog'lanish

[email protected]

Bizni kuzating

Instagram
Telegram
LinkedIn

Barcha huquqlar himoyalangan.

Foydalanish shartlari

Bosh sahifa
Kuzatuv
Bozorlar
Kalendar
Skriner
Yangiliklar
Biz haqimizda

PRGO - Perrigo Company plc So'nggi Yangiliklar | Finranks

Home

/

PRGO

P

Perrigo Company plc (PRGO)

NYQ – Real vaqt narxi. Valyuta: USD

12.37

-0.48 (-3.74%)

Bozor ochiq: Aug 12, 2026, 11:36 AM EDT

12.82

-0.03 (-0.24%)

Oldingi bozordan keyin: Aug 11, 2026, 7:34 PM EDT

Umumiy
Yangiliklar
Grafik
Hisobotlar
Dividendlar
Kutilma
Egalik
Profil

PRGO vs. NEOG: Which Stock Is the Better Value Option?

PRGO vs. NEOG: Which Stock Is the Better Value Option?

Investors with an interest in Medical - Products stocks have likely encountered both Perrigo (PRGO) and Neogen (NEOG). But which of these two companies is the best option for those looking for undervalued stocks?

Are Investors Undervaluing Perrigo (PRGO) Right Now?

Are Investors Undervaluing Perrigo (PRGO) Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Perrigo Q2 Earnings Call Highlights

Perrigo Q2 Earnings Call Highlights

Perrigo NYSE: PRGO reported second-quarter 2026 results that exceeded its internal earnings expectations, while sales declined amid soft consumer self-care categories, retailer inventory reductions and a slower start to seasonal demand. The company maintained its full-year outlook, citing improving category trends, market-share gains and expected second-half contributions from innovation, distribution and demand-generation efforts.

Perrigo Stock Rises 23% as Q2 Earnings & Sales Beat Estimates

Perrigo Stock Rises 23% as Q2 Earnings & Sales Beat Estimates

PRGO tops Q2 EPS estimates as Infant Formula sales jump, helping offset softer demand and divestiture impacts while the company reaffirms 2026 guidance.

Perrigo Company plc (PRGO) Q2 2026 Earnings Call Transcript

Perrigo Company plc (PRGO) Q2 2026 Earnings Call Transcript

Perrigo Company plc (PRGO) Q2 2026 Earnings Call Transcript

Perrigo (PRGO) Reports Q2 Earnings: What Key Metrics Have to Say

Perrigo (PRGO) Reports Q2 Earnings: What Key Metrics Have to Say

The headline numbers for Perrigo (PRGO) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Perrigo (PRGO) Surpasses Q2 Earnings and Revenue Estimates

Perrigo (PRGO) Surpasses Q2 Earnings and Revenue Estimates

Perrigo (PRGO) came out with quarterly earnings of $0.5 per share, beating the Zacks Consensus Estimate of $0.31 per share. This compares to earnings of $0.57 per share a year ago.

Videolar

No Data

There is no data to display

Press-relizlar

Perrigo Reports Second Quarter 2026 Financial Results From Continuing Operations

Perrigo Reports Second Quarter 2026 Financial Results From Continuing Operations

Execution of Three-S plan driving continued improvement in underlying business fundamentals, including market share growth in U.S. store-brand OTC and key European brands Streamlined portfolio through completion of Dermacosmetics divestiture and continuing strategic reviews of Infant Formula and Oral Care businesses Reaffirmed full-year 2026 outlook with sequentially stronger second-half performance DUBLIN, Aug. 5, 2026 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO) ("Perrigo" or the "Company"), a leading provider of Consumer Self-Care Products, today announced financial results from continuing operations for the second quarter ended June 27, 2026. "We continued to execute our Three-S plan in the second quarter, strengthening areas of the business within our control, improving operational performance, streamlining our portfolio, and further reducing debt," said Albert Manzone, Interim President and Chief Executive Officer.